Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma

Diseases of the Esophagus

Volumn 23, Issue 3, 2010, Pages 253-259

  Li, Q Q ^a,b   Liu, M Z ^a,b   Hu, Y H ^a,b   Liu, H ^a,b   He, Z Y ^a,b   Lin, H X ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cisplatin; Concurrent chemoradiotherapy; Docetaxel; Esophageal cancer

Indexed keywords

CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL; COUGHING; EARLY CANCER; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS STENOSIS; FEMALE; FOLLOW UP; HOARSENESS; HUMAN; LEUKOPENIA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA; THORACOCENTESIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; ADJUVANT THERAPY; CANCER STAGING; ESOPHAGUS TUMOR; FEASIBILITY STUDY; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; TAXOIDS; TREATMENT OUTCOME;

EID: 77957252640     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.01003.x     Document Type: Article

References (34)

1. Mariette C, Piessen G, Triboulet J P. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007; 8: 545-53.
2. van Meerten E, van der Gaast A. Systemic treatment for oesophageal cancer. Eur J Cancer 2005; 41: 664-72.
3. Smith T J, Ryan L M, Douglass J R et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42: 269-76.
4. Al-Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15: 277-84.
5. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus (Cochrane Review). Cochrane Database Syst Rev 2001; 2: CD002092.
6. NCCN. Clinical practice guidelines in oncology (esophageal cancer)-v.1.2009. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/esophageal.pdf
7. Cooper J S, Guo M D, Herskovic A S et al. Chemoradiotherapy of locally advanced esophageal carcinoma, long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999; 281: 1623-7.
8. Minsky B D, Pajak T F, Ginsberg R J et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-74.
9. Denis J N, Greene A E, Guenard D et al. A highly efficient practical approach to taxol. J Am Chem Soc 1988; 110: 5917-9.
10. Hennequin C, Giocanti N, Facaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996; 56: 1842-50.
11. Mason K A, Hunter N R, Milas M, Abbruzzese J L, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997; 3: 2431-8.
12. Tishler R B, Schiff P B, Geard C R, Hall E J. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613-7.
13. Xie F, Qi S, Hu W, Zou G-R, Peng M, Li J-S. Comparison of efficacy of doxetaxel combined cisplatin and cisplatin combined 5-Fluorouracil on locally advanced nasopharygeal carcinoma. Chin J Cancer 2007; 26: 880-4.
14. Halvorsen R A, Magruder-Habib K, Foster W L Jr, Roberts L Jr, Postlethwait R W, Thompson W M. Esophageal cancer staging by computed tomography long-term follow-up study. Radiology 1986; 161: 147-51.
15. Moss A A, Schnyder P, Thoeni R F, Marqulis A R. Esophageao carcinoma: pretherapy staging by computed tomography. AJR 1981; 136: 1051-56.
16. Picus D, Balfe D M, Koehler R E, Roper C L, Owen J W. Computed tomography in the staging of esophageal carcinoma. Radiology 1983; 146: 433-38.
17. Greene F L, Page D L, Flming I D et al. American Joint Committee on Cancer. AJCC Cancer Staging Handbook, 6th edn. Philadelphia, PA: Lippincott Raven, 2002.
18. GrahamMV, Purdy J A, Emami B et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for nonsmall cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45: 323-9.
19. Hernando M L, Marks L B, Bentel G C et al. Radiation induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001; 51: 650-9.
20. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-22.
21. Therasse P, Arbuck S G, Eisenhauer E A et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
22. ButtonMR, Morgan C A, Croydon E S, Roberts S A, Crosby T D. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiait Oncol Biol Phys 2009; 73: 818-23.
23. Roof K S, Coen J, Lynch T J et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1120-8.
24. Ringel I, Horwitz SB. Sudies with RP 56976 (Taxotere): a semisynthertic analogue of Taxol. J Nalt Cancer Inst 1991; 83: 288-91.
25. Van Cutsem E, Moiseyenko V M, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006; 24: 4991-7.
26. Pasini F, de Manzoni G, Pedrazzani C et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005; 16: 1133-9.
27. Maruyama S, Maruyama M, Tanami H et al. The docetaxel radiosensitization experience for the treatment of unresectable esophageal cancer. Gan To Kagaku Ryoho 2005; 32: 1724-6. (In Japanese.)
28. Hihara J, Yoshida K, Hamai Y, Emi M, Yamaquchi Y, Wadasaki K. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res 2007; 27 (4c): 2597-603.
29. Font A, Arellano A, Fernández-Llamazares J et al. Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clin Transl Oncol 2007; 9: 177-82.
30. Higuchi K, Koizumi W, Tanabe S et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluoroacil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol 2008; 87: 398-404.
31. Burmeister B H, Denham J W, O'Brien M et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiait Oncol Biol Phys 1995; 32: 997-1006.
32. Chen E-C, Liu M-Z, Hu Y-H et al. Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy. Chin J Cancer 2005; 24: 731-4.
33. John M J, Flam M S, Mowry P A et al. Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer 1989; 63: 2397-403.
34. Ishikura S, Nihei K, Ohstu A et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 14: 2697-702.